NitroMed

About:

NitroMed is an emerging pharmaceutical company with substantial expertise and intellectual property in nitric oxide-based drug development.

Website: http://www.nitromed.com

Top Investors: Care Capital, HealthCare Ventures, Rho Ventures, Johnson & Johnson Development Corporation, Morgan Stanley Expansion Capital

Description:

NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.